COMMUNIQUÉS West-GlobeNewswire

Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS
08/08/2018
Valby, Aug. 08, 2018 (GLOBE NEWSWIRE) -- HIGHLIGHTS Revenue reached DKK 9,288 million in the first six months of 2018 representing an increase of 9% (14% in local currencies) compared to the same period in 2017 Revenue [...]
VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS, RAISES FULL-YEAR GUIDANCE
08/08/2018
Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track Strategic in-licensing deal concluded with Cara Therapeutics Inc. Net sales and EBITDA guidance for 2018 raised and [...]
Bone Therapeutics SA Notice of Half Year 2018 Results
08/08/2018
Press release Bone Therapeutics Notice of Half Year 2018 Results Results to be announced on Thursday 30 August 2018 Gosselies, Belgium, 8 August 2018, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), [...]
Bone Therapeutics SA publiera ses résultats semestriels, le 30 août 2018
08/08/2018
Communiqué de presse Bone Therapeutics publiera ses résultats semestriels, le 30 août 2018 Gosselies, Belgique, le 8 août 2018, 7h00 CEST - BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de thérapie [...]
ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update
08/08/2018
Phase 2b EDELWEISS clinical trial of linzagolix (OBE2109) in endometriosis related pelvic pain achieved primary and secondary endpoints Chief Commercial Officer hired as nolasiban moves closer to commercialization Net [...]
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
08/08/2018
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public [...]
Zogenix Prices Public Offering of Common Stock
08/08/2018
EMERYVILLE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today [...]
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options
07/08/2018
--Advisory committee supports surrogate endpoint of sputum culture conversion-- --ALIS currently under FDA Priority Review; PDUFA action date set for September 28, 2018-- BRIDGEWATER, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE [...]
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
07/08/2018
-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD- -Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018- -Preclinical Studies for CTX110 Targeting CD19 [...]
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018
07/08/2018
Conference Call and Webcast Scheduled for Tuesday, August 14 at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear [...]
National Research Corporation Announces Second Quarter 2018 Results
07/08/2018
Strong Market Adoption of Digital Voice of Customer (VOC) Platform LINCOLN, Neb., Aug. 07, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2018. [...]
Atrion Reports Second Quarter Results
07/08/2018
ALLEN, Texas, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the second quarter ended June 30, 2018 revenues totaled $38.8 million compared with $36.2 million for the same [...]
Présentation de Merus lors de la conférence Wedbush PacGrow Healthcare 2018
07/08/2018
UTRECHT, Pays-Bas, 07 août 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), société d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics®), a [...]
XOMA Reports Second Quarter 2018 Financial Results
07/08/2018
EMERYVILLE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its second quarter 2018 financial [...]
Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
07/08/2018
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]
Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
07/08/2018
SAN FRANCISCO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by [...]
Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
07/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, [...]
Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
07/08/2018
--Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing [...]
Aptose Reports Results for the Second Quarter Ended June 30, 2018
07/08/2018
Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing [...]

Pages